Site brasileiro onde você pode comprar qualidade e entrega http://farmaciabrasilrx.com/ cialis barato em todo o mundo.

## Microsoft word - 5-08.doc

**On the Economics of Rational **
**Self-Medication **
**JANUARY 2008 **
SIEV – Sustainability Indicators and Environmental
Wisdom Akpalu,

*Center for Environmental Economics and Policy in Africa (CEEPA), *
*Agricultural Annex University of Pretoria *
This paper can be downloaded without charge at:
The Fondazione Eni Enrico Mattei Note di Lavoro Series Index:
http://www.feem.it/Feem/Pub/Publications/WPapers/default.htm
Social Science Research Network Electronic Paper Collection:
The opinions expressed in this paper do not necessarily reflect the position of
Corso Magenta, 63, 20123 Milano (I), web site: www.feem.it, e-mail: working.papers@feem.it

**On the Economics of Rational Self-Medication **

It has been established in the medical literature that self-medicating with imperfect information about either the use of a genuine or counterfeit drug or based on wrong self-diagnosis of ailment, which is predominant especially in developing countries, is a risky investment in health capital. This paper models the decision to self-medicate and the demand for self-medicated drugs. We suppose that investment in self-medication depends on the perception of its effectiveness. The results obtained show that the decision to self-medicate depends on the relative price and perceived effectiveness of self-medication, the elasticity of the shadow value of health with respect to the quantity of health capital, and the relative effectiveness of self-medication in reducing the unpredictable changes in health capital. Furthermore, if an individual self-medicates, self-medication becomes a normal good: it increases if income increases; and it obeys the law of demand (i.e. it increases if its price, relative to that of the risk-free medication, decreases). Moreover, we have shown that some optimum subsidy can discourage self-medication.

**Keywords:** Health Production, Self-Medication, Risky Investment, Government Policy,

Dynamic Analysis

**JEL Classification:** I12, I18, D81, C61

* Address for correspondence*: Wisdom Akpalu Center for Environmental Economics and Policy in Africa (CEEPA) Agricultural Annex University of Pretoria 0002 Pretoria South Africa E-mail: Wisdom.Akpalu@economics.gu.se, Wakpalu@yahoo.com

** **

While

*responsible* self-medication, which is limited to over-the-counter (OTC) drugs,

may generate substantial net benefit flows to economies through savings in travel and
consultation time and the direct financial cost of treatment (AESGP, 2004), some
conditions are necessary for these benefits to be realized. These conditions aim at
ensuring the safety of taking self-medicated drugs. They include the following: the drugs
used are those indicated for conditions that are self-recognizable; the user should know
how to take or use the drugs; the effects and possible side-effects of the drugs as well as
ways of monitoring these side-effects are well communicated to the user; possible
interactions with other drugs is known by the user; duration of the course of the drugs is
known by the user and, when the user must seek professional intervention (WHO, 1998).
The consequences for incorrect diagnosis and dosage include growing resistance to some
drugs and further deterioration in health capital.
Unfortunately, especially in developing countries, professional health care is
relatively expensive and in some cases not readily available thereby making self-
medication an obvious choice of health care service (Chang and Trivedi, 2003; Phalke et
al., 2006). Furthermore, it has been noted that purchases of prescription-only drugs are
far more than the purchase of OTC drugs (Chang and Trivedi, 2003; WHO, 2001) and
many drugs that can only be purchased with prescription in developed countries are OTC
in developing countries (Chang and Trivedi, 2003). Also, lax medical regulations have
resulted in the proliferation of counterfeit drugs that are in high demand for the treatment
of highly prevalent diseases such as malaria (see e.g. Shakoor et al., 1997; WHO, 1999;
Rogendaal, 2001; Basco, 2004). For example, a study by Basco (2004) in Africa on the
use of chloroquine, quinine and antifolates showed that about 30%, 74% and 12% of
these malaria drugs respectively had either no active ingredient, insufficient active
ingredient, the wrong ingredient or an unknown ingredient. Moreover, a considerable
number of studies have also highlighted the potential dangers of self-medication (Levy,
1992; Mudur, 1999; WHO, 2001). As a result, taking a self-medicated drug is a risky
Although self-medication is very common and expected to grow as a result of the
use of the internet to market drugs and deregulation of OTC sale of drugs with

*active*
ingredients (see e.g. Chang and Trivedi, 2003; Phalke et al., 2006), economic models for
such a risky investment in health capital are very scarce. The only attempt at modeling
the economics of self-medication is by Chang and Trivedi (2003) who developed a static
model based on choice under uncertainty. In their model, the individual allocates her
budget between the consumption of a composite good, a self-medicated drug and
professional care. While professional care is assumed to be risk-free, self-medication is
not. The main results from their theoretical model are as follows: First, self-medication
obeys the law of demand. Second, self-medication is an inferior good. Third, riskier self-
medication will increase the demand for professional care. While the first and the third
results were confirmed by their data, they found that self-medication was a normal good
for the low-income group (i.e. 50th percentile) and an inferior good for the high-income
group. Like Chang and Trivedi (2003), this paper assumes that the individual maximizes
utility from consuming a composite good and a state of health. However, we extend this
work in a number of ways. First, since health capital is a state variable that evolves
overtime in a partly uncertain manner due to unexpected ailments, we present the state of
health equation as a stochastic dynamic equation (see e.g. Grossman, 1972; Cropper,
1977; Reid, 1996; Picone et al., 1997; Sidorenko, 2001 for stochastic models of health);
second, total expenditure on medication within a period of time is the expected
expenditure on self-medication and risk-free medication, where the probability weights
are based on the individual’s perception of the effectiveness of the self-medicated drug
and the risk-free medication2; third, the expected health benefit from self-medication
depends on perceived effectiveness of self-medication. Moreover, in this paper, the
marginal conditions in the presence of self-medication and risk-free medication only have
been compared to determine the optimal subsidy necessary to discourage self-medication.
1 Self-medication is considered risk-free if and only if it is limited to an OTC drug that is not counterfeited. 2 Note that commitment to self-medication only is not feasible, since the individual has to resort to prescribed medication if self-medication fails.
The results obtained from the optimization program indicates that the decision to
self-medicate depends on the relative price of the two medications (i.e. an individual may
switch to self-medication if it becomes relatively cheap), the perceived effectiveness of
self-medication, the elasticity of the shadow value of health with respect to the quantity
of health capital and the relative effectiveness of self-medication in reducing the
uncertain component of the dynamics of the health capital. Furthermore, our results
illustrate that self-medication is a normal good for those who engage in it: thus, it
increases if income increases; and it obeys the law of demand (i.e. it increases if its
relative price decreases). Finally, the optimal subsidy that can discourage self-medication
must be decreasing in both the relative price and the perceived effectiveness of the self-
medicated drug but increasing in the elasticity of the shadow value of the health with
respect to the quantity of health capital, if the self-medicated drug is more effective in
reducing the unexpected shocks to health capital. On the other hand, if the two
medications are equally effective in reducing the stochastic component of the dynamics
of the health capital, the subsidy is just the price difference between the two medications.
The rest of the paper is organized as follows: The model is presented in section 2
followed by the economic policy instrument in section 3. The last section presents the
conclusions and the discussions of the paper.

** **

*A stochastic model of self-medication: finding the optimal usage *

Suppose a representative individual derives utility

*u*(

*c*,

*h*) from her state of health

*h * and

the consumption of a composite good

*c *. Furthermore, assume that the utility is
increasing in the two arguments (i.e.

*u *> 0 ,

*u *> 0 , where the subscripts denote partial
derivatives), the individual’s life expectancy is

*T *years, and future states of health is
discounted at the rate δ , δ > 0 . The objective function of the individual is to maximize
the expected value of the discounted stream of utility (i.e. equation 1), where

*E * is an

*Max V *=

*E u*(

*c*,

*h*)

*h *≥ . Let the health capital or the state of health evolve according to a
stochastic dynamic process defined by the function:

*dh *= (

*s*(

*y*,

*g*) −α )

*hdt *−σ (

*s*(

*y*,

*g*))

*hdz *, (2)
From this equation,

*s *=

*s*(

*y*,

*g*) is the health benefit from self-medicated and risk-
free (e.g. prescribed) drugs (i.e.

*y *and

*g *, respectively) used by the individual and the
constant α is the net natural depreciation of the health capital. The term σ (.) defines the
volatility or the variance of the health state dynamics,

*z *is a Weiner process and

*dz *is the
change in the stochastic process. Note that we assume that the variance is linearly related
to

*s *, with a drift term. Thus, the equation has a deterministic component, which is the
first term in the right hand side, and a stochastic or uncertain component, which is the last
term of the right hand side. Beginning with the seminal paper of Grossman (1972), a
number of studies have modeled health state as a dynamic process (see e.g. Picone et al.,
1998). Also, Arrow (1963) introduced uncertainty in the incidence of illness in health
care delivery. A number of studies have combined uncertainty and dynamics in modeling
health capital (see e.g. Picone et al., 1998; Sidorenko, 2001).
The individual has to complement self-medication with professional medical care
if the self-medication fails. As a result, the agent cannot solely depend on self-
medication. Let

*m * be real disposable income within a period of time

*t *;

*p * and

*q * are
perfect competitive relative prices of the composite good

*c * and self-medicated drug

*y *
respectively, with risk-free medication

*g * being the numeraire. Furthermore, let

*v * be a
subjective probability defining how effective the self-medicated drug is perceived to be.
If it is perceived to be as effective as the prescribed drug, then

*v *= 1 and the agent is
indifferent between using a self-medicated or prescribed drug. Consequently, the agent
will invest in only a self-medicated drug if it is less expensive (i.e.

*m *=

*qy *+

*pc * if all the
budget is spent). On the other hand, if the self-medicated drug is perceived to be
completely ineffective then

*v *= 0 , which implies that only the prescribed drug will be
purchased. However if self-medication is present but the drug is perceived not to be
completely effective, then

*v *∈ (0,1) . Therefore the term

*qvy *+ (1−

*v*)

*g * defines expected
expenditure on medication if self-medication is present. Note that the expenditure on the
self-medicated drug increases as

*v * increases. The budget constraint facing the agent
within a period of time, say one year, is:

*m *=

*pc *+

*qvy *+ (1−

*v*)

*g *.
We have supposed for simplicity, but without compromising generality, that there
is no inter-temporal transfer of income between periods3. Moreover, the equation
assumes that the entire budget is expended within each period. Note that although the
expenditure on either the self-medicated drug or prescribed drug is stochastic, the
probability is just a weight, which defines how the budget on the drugs is allocated.
Consequently, the expected and actual expenditure should be equal in each period. Thus,
like Chang and Trivedi (2003) a partial equilibrium approach is taken to model demand
for health where the representative agent allocates her entire disposable income to health
care and other composite commodities within each period. Moreover, it is supposed that
the state of health does not affect the disposable income. It is noteworthy that this mimics
the situation in many economies (especially developing countries) where fixed-income
earners e.g. salary workers who receive fixed disposable income hardly save or have easy
access to credit from formal financial institutions to finance consumption. It is also noted
that the poor in developing countries hardly save or have easy access to credit (Aryeetey,
The Bellman equation associated with equations (1) through (3) writes
3 The budget constraint has been specified as wealth (

*w *) dynamic equation by some studies, e.g. Picone
(1998). In our case it could be specified as

*dw *= (

*rw *−

*pc *−

*vqy *− (1−

*v*)

*g *)

*dt *. If it is assumed for
simplicity that

*dw dt *= 0 and

*rw *=

*m *, then equation (3) is obtained.
Using Ito’s lemma, we have the following definition
By substituting

*dh *from equation (2) into equation (5), we have

*y g *−α )

*hdt *−σ (

*s y g *)

*hdz*)

*V*
+ ((

*s*(

*y*,

*g*) −α )

*hdt *−σ (

*s*(

*y*,

*g*))

*hdz*) 2
If equation (5´) is expanded, noting that for Weiner processes the following apply:

*dtdt *= 0 ,

*dzdz *=

*dt *,

*E *(

*dz *) = 0 and

*dtdz *= 0 , we have

*E *(

*dV *(

*h*)) = (

*s*% −α )
where

*E*(

*s*) =

*s*% . Using equation (6), the Bellman’s equation can be rewritten as
⎨ (

*c*,

*h*) + (

*s*% −α )
Following Xepapadeas (1997), the corresponding current value Hamiltonian
representation of equation (7) is equation (8). Note that λ
the state of health. Moreover, since the disposable income is fixed, equation (9)
represents the Lagrangean function for the optimization program, which is the sum of the
current value Hamiltonian and the budget constraint.

*H *=

*u*(

*c*,

*h*) + λ (

*s*% −α )

*L *=

*H *+ ω (

*m *−

*pc *−

*vqy *− (1−

*v*)

*g *) .
The first order condition of equation (9) with respect to the choice variables:

*c *,

*y *and

*g *; and the Lagrangean multiplier ω are equations (10) through (13) respectively.
The corresponding costate equation is equation (14).

*v*ω

*q *= λ

*hs *+

*h *λ

*E*σ

*s *.
ω(1−

*v*) = λ

*hs *+

*h *λ

*E*σ

*s *.
∂ = 0 →

*m *=

*pc*+

*vqy *+(1−

*v*)

*g*
λ −σ (

*s*)

*h *λ −

*u *.
The interpretation of equation (10) is straightforward: in equilibrium, the marginal
utility obtained from consuming the composite good (i.e.

*u *=
the utility of the price of the good (i.e. ω

*p *). Rewriting equations (11) and (12), and using
η = λ is the elasticity of the shadow value of health with respect to the quantity
of health capital (i.e. how sensitive the value an individual places on her health capital is
to a change in her state of health). Consequently, the weighted sum of the marginal health
benefits if self-medication is present is

*h *⎜ λ

*p *(1 η

*E*σ ⎟
From equation (15), the expected health benefit from a marginal increase in the use of the
self-medicated and prescribed drugs (i.e.

*s*% +

*s*% ) must reflect some adjusted marginal
opportunity cost of the composite good per unit of the health capital (i.e. the term at the
right hand side of the equation). Note that

*v * and

*E*σ appear in equation (15) due to the
individual’s perceived uncertainty about how effective the self-medicated drug is and the
uncertainty about the health dynamics of her health capital respectively.
If the individual does risk-free medication, the optimization program becomes
maximizing equation (1) subject to the following constraints

*w g*) is the health benefit from risk-free medication only. The corresponding
Bellman’s equation is equation (18), and the Hamiltonian and the Lagrangean functions
are equations (19) and (20) respectively.
⎨ (

*c*,

*h*) + (

*w *−α

*h*)

*H *=

*u*(

*c*,

*h*) + λ (

*w *−α

*h*) 1

*L *=

*H *+ ω (

*m *−

*pc *−

*g *) .
The first order derivative of equation (20) with respect to

*c * and

*g *gives equations
ω = λ

*hw *+σ

*w h *λ . (22)
The corresponding costate equation is the same as equation (14). Again, using equation
(21), equation (22) could be rewritten as:
Note that

*w * is the marginal health benefit from risk-free medication only.

** **

*The optimal condition for self-medication *

In this section the optimal condition for self-medication is derived.

**Proposition 1**:

*The (necessary) condition for self-medication is v *≥

*condition for self-medication for all v *∈ (0,1)

* is E*σ ≥ σ

*. On the other hand, self-*
*medication will not occur if E*σ < σ .

**Proof**. The proof requires comparing the weighted sum of the marginal health benefit if

the individual self-medicates to the benefit without self-medication. Thus,
Rearranging the terms in equation (23) gives
is some adjusted relative effectiveness of self-medication in
reducing the uncertain component of the change in health capital. Moreover, since

*q *∈ (0,1) , the condition that self-medication will occur for all

*v *∈ (0,1) is

*A *≥ 1 (i.e.

*E*σ ≥ σ ). Thus, if the price of the self-medicated drug is lower than that of the risk-free
drug, self-medication will be present if the self-medication, on the average, is more
effective (relative to the risk-free medication) in reducing the uncertain component of the
dynamics of the health capital. On the other hand, if

*q *>

*A * self-medication will not
occur since the perceived probability cannot be greater than 1 (i.e.

*v *∉ (0,1) . But

*q *>

*A *
implies that

*q *(1+ησ ) > 1+η

*E*σ . Since

*q *∈ (0,1) , it follows that 1+ησ > 1+η

*E*σ

** **

Lemma 1:

*The likelihood of self-medicating will increase if the price of the self-*
*medicated drug decreases or if the perception of the effectiveness of self-medication *
should hold for an individual to self-medicate, it follows that
self-medication will not occur if

*v *<
. However, a sufficient reduction in

*q * could
change the sign and make self-medication worthwhile. Thus, any policy that increases the
cost of accessing professional health care may encourage individuals to switch to self-
medication. Furthermore, all other things being equal, an increase in

*v * for example
through a public campaign on the effectiveness of a self-medicated drug will encourage
individuals who do risk-free medication to take the drug.■

** **

*The extent of self-medication *

** **

Given that the representative agent self-medicates, this section discusses the extent to

which self-medication is done. To facilitate the discussion, some specific forms of the
functions in the preceding sections are assumed. Suppose there is diminishing marginal
health benefit from increased usage of a prescribed or a self-medicated drug so that

*w g*) =

*kg *, where

*k *> 0 and β ∈ (0, )
1 . Furthermore, let the health benefit that an
individual obtains if she self-medicates be the weighted sum of the benefit from taking
the self-medicated and prescribed drugs, with the weights being

*v *. Thus,
+ (1−

*v*)

*g *) and

*E s *=

*s*% =

*k *(
ε + (1−

*v*)

*g *), where ε is a
random variable which takes positive or negative values and has the following moments:
ε . Furthermore, assume the subjective probability of the
effectiveness of the self-medicated drug is based on experience so that the relationship
between ε and ν is defined by a cumulative probability density function. Let this
ε , which implies that 1−

*v *=

*e*
ln(1

*v*) . Figure 1 depicts the probability density function of the
effectiveness of self-medication. Note that

*f *(ε ) is the probability density function and
the shaded area of the graph defines the perceived subjective probability of non-
effectiveness of the self-medicated drug.

**Figure 1***: Probability density function of the effectiveness of self-medication *
Using this definition, dividing equation (11) by (12) and solving for

*g *gives
. The budget constraint can therefore be re-specified as
Note that if

*e * is non-stochastic, then

*E*(

*e*
ε if

*E*(ε ) = μ and var(ε ) = σε .
⎛

*m *−θω ⎞ ⎛

*vq *⎞
⎝ 1−

*v *⎠ ⎝1−

*v *⎠
⎛

*m *−θω ⎞ ⎛

*vq *⎞
⎝ 1−

*v *⎠ ⎝1−

*v *⎠
Figure 2 depicts the graph of equations (25) and (26). As can be inferred from the
equations and seen from the figure, the model gives a unique equilibrium solution.
However, since it is impossible to obtain close-form solutions for *
equation (27) using existing mathematical software, the following section is devoted to

*g *= ((

*m *−θω ) (1−

*v*)) − (

*vq *1−

*v*)

*y *
**Figure 2***: Equilibrium quantity of risk-free and self medicated drugs*** **

*Numerical simulation of the extent of self-medication *

** **

In this section, some parameter values are used to simulate the equilibrium relationship
between equations (25) and (26). The values are chosen to satisfy the a priori restriction
on the parameters. Thus, β ,

*v*,

*q *∈ (0,1) ;

*m *> 0 and θω > 0 . The results presented in Table
1 are based on a simple numerical simulation of equation (27). First, the results show that
self-medicated drug obeys the law of demand. From the table, a decrease in the relative
price of the self-medicated drug results in an increase in the demand for the self-
medicated drug and a decrease in the demand for the risk-free medication (i.e.
> 0 ). This result can be seen by comparing the figures in the baseline column to
that of the fourth column (i.e. for

*q *↓ ). Moreover, the self-medicated drug is a normal
good. Thus, a reduction in the disposable income (i.e.

*m *↓ )

* *decreases the demand for
both the self-medicated drug and the risk-free medication (i.e.
Second, the results indicate that there is an inverse relationship between the
quantities of the self-medicated drug and risk-free medication that is taken on one hand,
and the effectiveness of self-medication on the other. From the last column of Table 1, an
increase of

*v * from 0.5 to 0.7, all other things being equal, decreased the use of both the
self-medicated and risk-free drugs (i.e.
terms, the use of self-medicated drug is intensified several fold (i.e. *
Table 1. Simulated values of real expenditure on self-medicated and risk-free drugs.

**24.2 19.2 32.2 17.1 **
**0.135642 0.135335 0.090183 0.009393 **
**178.41 141.87 357.05 1820.50 **
3. Economic incentive to discourage self-medication
As noted earlier, due to lack of adequate knowledge on some drugs, the proliferation of
counterfeit drugs and the sale of prescription-only drugs as OTC drugs, self-medication
remains a risky investment in health capital. Moreover, any reduction in health capital
may impact negatively on the productive capacities of economies. As a result, policy
interventions may be required to discourage self-medication. In this section, an attempt is
made at obtaining such a policy instrument. Suppose an individual prefers self-
medication to risk-free medication (i.e.

*E*σ > σ ), a subsidy rate of τ that makes
equation (24) hold with equality could be defined. Thus, an expression where the
individual is indifferent between self-medication and taking risk-free medication is

**Proposition 2**.

*The subsidy must be decreasing in the relative price of the drugs and the *
*perceived probability of effectiveness of self-medication, but increasing in the elasticity of *
*the shadow value of health with respect to the quantity of health capital if A *> 1

*. *
**Proof**. The proof for proposition 2 requires taking partial derivatives of equation (29)

with respect to the parameters

*q ***, ***v * and η ; and looking at the sign of the derivatives. The

corresponding results are presented below.
Thus, if it becomes more expensive to self-medicate, a lower subsidy rate is necessary to
discourage self-medication. Furthermore, if it is less risky to self-medicate, the subsidy
must decrease. Moreover, the subsidy must increase if the elasticity of the shadow value
of health with respect to the quantity of health capital increases. This is because, if self-
medication is more effective in reducing the unpredictable changes in the state of health,
then the more an individual values her state of health, the more she self-medicates. A
higher subsidy is therefore necessary to discourage such an individual from self-

**Proposition 3**.

*The subsidy must be decreasing in the relative price of self-medicated and *
*risk-free or prescribed drugs but neither sensitive to a change in perceived probability of *
*effectiveness of the self-medicated drug nor the elasticity of the shadow value of health *
*with respect to the quantity of the health capital if A *= 1

*. *
** **

Proof. If

*A *= 1 , then equation (29) becomes τ = 1−

*q *. Consequently,

** **

Thus, if the individual perceives the self-medicated drug on the average, as effective as

the risk-free or prescribed drug in reducing the uncertain component of the health capital,
then self-medication can only be discouraged if the price differentials between the self-
medicated and risk-free or prescribed drugs are eliminated.
In developing countries, professional health care is relatively expensive and in some
cases completely absent. This situation has created high demand for self-medicated drugs
for the treatment of highly prevalent diseases such as malaria. Incorrect diagnosis and
dosage, the availability of prescription-only drugs as OTC medication and lax
pharmaceutical policies that are leading to proliferation of counterfeit drugs contribute to
making self-medication a risky investment in health capital. Although self-medication is
common, economic models for such a risky investment are very scarce, with the only
exception being the static model of Chang and Trivedi (2003). This paper extends the
static model to a stochastic dynamic one, for two situations: where self-medication is
The results obtained show that an individual may resort to self-medication if the
price of self-medicated drugs decreases relative to that of risk-free medication. Secondly,
self-medication could occur if the individual perceives that its effectiveness has
increased. Third, self-medication could occur if the elasticity of the shadow value of
health with respect to the quantity of health capital increases and if self-medication is
relatively more effective in reducing the uncertain component of the dynamics of health
capital. Furthermore, self-medication increases if income increases, which makes it a
normal good; and it obeys the law of demand. Finally, it has been shown that some
optimal subsidy could be used as an economic incentive to discourage self-medication.

** **

References
AESGP (2004).

*The* *Economic and Public Health Value of Self-Medication*. Brussels,
Belgium. http://www.aesgp.be/ResearchProject/FinalReport.pdf
Arrow, K. J. (1963). Uncertainty and the Welfare Economics of Medical Care.

*The *
*American Economic Review *53(5): 941-73.
Aryeetey, E. (1994). Financial Integration and Development in Sub-Saharan Africa: A
Study of Informal Finance in Ghana.

*Mimeo*. (Processed), Overseas Development
Basco, L. K. (2004). Molecular Epidemiology of Malaria in Cameroon. Xix. Quality Of
Anti-malarial Drugs Used for Self-Medication.

*American Journal of Tropical Medicine *
Chang, F-R. and P. K. Trivedi (2003). Economics of Self-medication: Theory and
Evidence.

*Health Economics* 12: 721–739.
Chang, F. (1996). Uncertainty and Investment in Health.

*Journal of Health Economics*
Cropper, M. L. (1977). Health, Investment in health, and Occupational Choice.

*Journal *
*of Political Economy* 85, 1273–1294.
Grossman, M. (1972

*). *On the Concept of Health Capital and the Demand for Health.

* *
*Journal of Political Economy *80, 223-55.
Hjortsberg, C. (2003). Why do the Sick not Utilize Health Care? The case of Zambia.
Levy, S. B. (1992). The Antibiotic Paradox: How Miracle Drugs are Destroying the
Mudur, G. (1999). Abuse of OTC Drugs Rising in South Asia.

*British Medical Journal*
Phalke. V. D., D. B. Phalke and P.M. Durgawale (2006).

* *Self-Medication Practices in
Rural Maharashtra.

*Indian Journal of Community Medicine* 31(1): 34-35.
Picone, G., M. Uribe and R. M. Wilson (1998). The Effect of Uncertainty on the Demand
for Medical Care, Health Capital and Wealth.

*Journal of Health Economics* 17: 171–185.
Ried, W. (1996). Willingness to Pay and Cost of Illness for Changes in Health Capital
Depreciation.

*Health Economics* 5: 447–468.
Rogendaal, J. (2001). Fake Antimalaria Drugs in Cambodia (letter).

*Lancet *357: 890.
Shakoor, O., R. B. Taylor and R. H. Behrens (1997). Assessment of the Incidence of
Substandard Drugs in Developing Countries.

*Tropical Medicine & International Health *
Sidorenko, A. (2001). Stochastic Model of Demand for Medical Care with Endogenous
Labour Supply and Health Insurance.

*Working Papers in Trade and Development *
*2001/08*. Australian National Development.
Viscusi, W. and W. Evans (1990). Utility Functions that Depend on Health Status:
Estimates and Economic Implications.

*American Economic Review* 3 (81): 353–374.
WHO (1998).

*The Role of the Pharmacist in Self-Care and Self-Medication: Report of *
*the 4th WHO Consultative Group on the Role of the Pharmacist*. The Hague, The
WHO (1999).

*Counterfeit Drugs. Guidelines for the Development of Measures to Combat *
*Counterfeit Drugs. *Geneva, World Health Organization. WHO/EDM/QSM/99.1.
WHO (2001). General Policy Information.

*WHO Drug Information* 14: 1–2.
Xepapadeas, A. (1997)

*Advanced Principles in Environmental Policy*. Northhampton,

**NOTE DI LAVORO DELLA FONDAZIONE ENI ENRICO MATTEI **
**Fondazione Eni Enrico Mattei Working Paper Series **
**Our Note di Lavoro are available on the Internet at the following addresses: **
http://www.feem.it/Feem/Pub/Publications/WPapers/default.htm

**NOTE DI LAVORO PUBLISHED IN 2008 **
*Valentina Bosetti, Carlo Carraro and Emanuele Massetti*: Banking Permits: Economic Efficiency and Distributional Effects

*Ruslana Palatnik and Mordechai Shechter*: Can Climate Change Mitigation Policy Benefit the Israeli Economy? A Computable General Equilibrium Analysis

*Lorenzo Casaburi, Valeria Gattai and G. Alfredo Minerva*: Firms’ International Status and Heterogeneity in Performance: Evidence From Italy

*Fabio Sabatini*: Does Social Capital Mitigate Precariousness?

* *
*Wisdom Akpalu*: On the Economics of Rational Self-Medication

**2008 SERIES **
*Climate Change Modelling and Policy * (Editor: Marzio Galeotti )

*Sustainability Indicators and Environmental Valuation *(Editor: Anil Markandya)

*Natural Resources Management* (Editor: Carlo Giupponi)

*Knowledge, Technology, Human Capital *(Editor: Gianmarco Ottaviano)

*International Energy Markets *(Editor: Matteo Manera)

*Corporate Social Responsibility and Sustainable Management *(Editor: Giulio Sapelli)

*Privatisation Regulation Corporate Governance* (Editor: Bernardo Bortolotti)

* *
*Economic Theory and Applications *(Editor: Carlo Carraro)

Source: http://www.feem.it/userfiles/attach/Publication/NDL2008/NDL2008-005.pdf

Spring Plant Sale-2013 Actaea ramosa 'Burgundy' Actaea ramosa 'Pink Spike' Aeonium- assorted coloursAgastache 'Blue Fortune' Alchemilla erythropodaAquilegia 'Biedermeier Mix' Aquilegia caerulea 'McKana's Giants Mix' Aquilegia vulgaris 'Clementine Blue'Aquilegia vulgaris 'Clementine Dark Purple'Aquilegia vulgaris 'Clementine Red'Aquilegia vulgaris 'Clementine Rose'Aquilegia vulgaris var. stel

Überall im Internet und auch im Supermarkt nebenan, in der Apotheke oder im Reformhaus können Sie Ginseng-Produkte kaufen. Aber Ginseng ist nicht gleich Ginseng . Deshalb habe ich Ihnen einige Tips zusammengestellt, damit Sie für Ihr Geld ein gutes Produkt erhalten. Wenn sie weitere Fragen haben, rufen Sie mich bitte an: 05521-8490204 . Unter dieser Telefonnummer stehe ich Ihnen persönlic